Actions and Detail Panel
Psychedelics 101 for Clinicians
Sat, May 6, 2017, 10:00 AM – 5:00 PM EDT
While the use of psychedelic substances, such as psilocybin, ayahuasca, MDMA and LSD, remains tightly controlled in the United States, the reality is that many individuals continue to make use of these substances in a variety of settings and contexts. Despite the potential benefits psychedelics may offer, there are real risks associated with their unsupervised use, and few clinicians have received the necessary education and training to provide optimal care to individuals who use psychedelics and their families.
This day-long training offered through the The Psychedelic Education and Continuing Care Program is designed specifically for mental health and substance abuse treatment professionals, as well as other clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to best work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics.
The workshop will be taught by Katherine MacLean, PhD and Ingmar Gorman, PhD(c), co-founders and directors of The Psychedelic Education and Continuing Care Program, along with Dr. Andrew Tatarsky, director of the Center for Optimal Living in New York. The workshop will include lecture, Q/A/discussion, and interactive components. We will cover the basics of psychedelic science as it pertains to medical and psychological health, current findings from clinical trials of psilocybin, LSD, ayahuasca and MDMA, and the basics of psychedelic harm reduction and assessment in a clinical setting. We will also discuss the process of psychedelic integration in both individual and group therapy, with an emphasis on our client-centered approach through integrative harm reduction psychotherapy.
Katherine MacLean, Ph.D., is the Director of the Psychedelic Education and Continuing Care Program and a trained research scientist with a long-standing interest in the brain and the science of well-being. At the University of California, Davis, Katherine was supported by a NSF research fellowship to study the effects of mindfulness on well-being and brain function. As a postdoctoral research fellow and faculty member at the Johns Hopkins University School of Medicine, she worked with Dr. Roland Griffiths and his team. Her research on psilocybin and personality change suggests that this class of medicines may play an important role in enhancing mental health, and promoting emotional well-being and creativity throughout the lifespan. Katherine's current focus is on integration, or the process and methods by which psychedelic and other intense or difficult life experiences become incorporated over time into a person's life in a way that benefits the person and their community. She leads monthly psychedelic integration support groups and experiential workshops in New York.
Ingmar Gorman, PhD(c), is the Administrative Director of the Psychedelic Education and Continuing Care Program and a doctoral student in Clinical Psychology at the New School for Social Research. After receiving his B.A. from the New College of Florida, Ingmar served as a research assistant at the Prague Psychiatric Center and later at the Memorial Sloan Kettering Cancer Center. He received clinical training at Mount Sinai/Beth Israel Hospital, Bellevue Hospital, and at the Columbia University Center for Psychoanalytic Training and Research. He is currently continuing his training at Bellevue Hospital for his clinical internship year. Ingmar conducts psychotherapy research in MDMA-assisted psychotherapy for PTSD at the Multidisciplinary Association for Psychedelic Studies (MAPS). Ingmar’s primary interests include psychotherapy variables in drug-assisted psychotherapy, therapist training, psychoanalysis, and Integrative Harm Reduction Psychotherapy for substance misuse.
Andrew Tatarsky, PhD, is an internationally recognized leader in the treatment of substance misuse and other potentially risky behaviors. He has specialized in the treatment of addiction for 30 years as a counselor, psychologist, program director, trainer, advocate and author. He has devoted his career to developing a comprehensive understanding of the broad spectrum of substance use problems and an integrative harm reduction psychotherapy approach to treating this spectrum. This treatment is described in his book, Harm Reduction Psychotherapy: A New Treatment for Drug and Alcohol Problems, and several professional papers and book chapters that extend the approach. Dr. Tatarsky is Founder and Director of the Center for Optimal Living, where treatment and professional training is based on Integrative Harm Reduction Therapy (IHRP). He earned his doctorate in clinical psychology from the City University of New York. He is a Clinical Advisor to the Office of Alcoholism and Substance Abuse Services of New York State, Founding board member and President-elect of the Division on Addiction of New York State Psychological Association, Board Member of Moderation Management Network, founding board member of Association for Harm Reduction Therapy and Chairman of Mental Health Professionals in Harm Reduction and Faculty, Advanced Specialization in Family and Couple Therapy, The Postdoctoral Program in Psychotherapy and Psychoanalysis, New York University.